Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis

Journal of Medical Microbiology

Volumn 49, Issue 7, 2000, Pages 601-606

  Dannaoui, E ^a   Borel, E ^a   Persat, F ^a   Piens, M A ^a   Picot, S ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ERGOSTEROL; ITRACONAZOLE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS TERREUS; CONTROLLED STUDY; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEROL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME;

EID: 0033937549     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-49-7-601     Document Type: Article

References (34)

1. 1. Iwen PC, Rupp ME, Langnas AN, Reed EC, Hinrichs SH. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis 1998; 26: 1092-1097.
2. 2. Lass-Flörl C, Kofler G, Kropshofer G et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998; 42: 497-502.
3. 3. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-803.
4. 4. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother 1990; 34: 183-188.
5. 5. Dannaoui E, Persat F, Monier M-F, Borel E, Piens M-A, Picot S. In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J Antimicrob Chemother 1999; 44: 553-555.
6. 6. Oakley KL, Moore CB, Denning DW. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother 1999; 43: 1264-1266.
7. 7. Verweij PE, Oakley KL, Morrissey J, Morrissey G, Denning DW. Efficacy of LY303366 against ampholericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother 1998; 42: 873-878.
8. 8. Odds FC, Van Gerven F, Espinel-Ingroff A et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 1998; 42: 282-288.
9. 9. Vanden Bossche H, Dromer F, Improvisi I, Lozano-Chin M, Rex JH, Sanglard D. Antifungal drug resistance in pathogenic fungi. Med Mycol 1998; 36 Suppl 1: 119-128.
10. 10. Espinel-Ingroff A, Dawson K, Pfaller M et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995; 39: 314-319.
11. 11. Espinel-Ingroff A, Bartlett M, Bowden R et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol 1997; 35: 139-143.
12. 12. NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts. M-27A. Villanova, PA, National Committee for Clinical Laboratory Standards. 1995.
13. 13. Michallet M, Persat F, Kranzhofer N et al. Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. Bone Marrow Transplant 1998; 21: 1239-1243.
14. 14. Warnock DW, Turner A, Burke J. Comparison of high performance liquid Chromatographic and microbiological methods for determination of itraconazole. J Antimicrob Chemother 1988; 21: 93-100.
15. 15. Quail MA, Arnoldi A, Moore DJ, Goosey MW, Kelly SL. Ketoconazole-mediated growth inhibition in Botrytis cinerea and Saccharomyces ccrevisiae. Photochemistry 1993; 32: 273-280.
16. 16. Loeffler RST, Hayes AL. Effects of sterol biosynthesis inhibitor fungicides on growth and sterol composition of Ustilago maydis, Botrytis cinerea and Pyrenophora teres. Pestic Sci 1992; 36: 7-17.
17. 17. Loeffler RST, Hayes L. Sterols of the plant pathogenic fungi Botrytis cinerea and Pyrenophora teres. Phytochemistry 1990; 29: 3423-3425.
18. 18. Weete JD, Gandhi SR. Sterols of the phylum zygomycota: phylogenetic implications. Lipids 1997; 32: 1309-1316.
19. 19. Denning DW, Hanson LH, Perlman AM, Stevens DA. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992; 15: 21-34.
20. 20. Dannaoui E, Borel E, Persat F, Monier MF, Piens MA and EBGA Network. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. J Med Microbiol 1999; 48: 1087-1093.
21. 21. Denning DW, Marinus A, Cohen J et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. J Infect 1998; 37: 173-180.
22. 22. Sokol-Anderson M, Sligh JE, Elberg S, Brajtburg J, Kobayashi GS, Medoff G. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob Agents Chemother 1988; 32: 702-705.
23. 23. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401-414.
24. 24. Denning DW, Venkateswarlu K, Oakley KL et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1364-1368.
25. 25. Kelly SL, Lamb DC, Kelly DE, Loeffler J, Einsele H. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 1996; 348: 1523-1524.
26. 26. Nolte FS, Parkinson T, Falconer DJ et al. Isolation and characterization of fluconazole-and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997; 41: 196-199.
27. 27. Kelly SL, Lamb DC, Taylor M. Corran AJ, Baldwin BC, Powderly WG. Resistance to amphotericin B associated with defective sterol Δ 8 → 7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol Lett 1994; 122: 39-42.
28. 28. Hitchcock CA, Barrett-Bee KJ, Russell NJ. The lipid composition and permeability to azole of an azole-and polyene-resistant mutant of Candida albicans. J Med Vet Mycol 1987; 25: 29-37.
29. 29. Kim SJ, Kwon-Chung KJ, Milne GWA, Prescott B. Polyene-resistant mutants of Aspergillus fennelliae: identification of sterols. Antimicrob Agents Chemother 1974; 6: 405-410.
30. 30. Mbongo N, Loiseau PM, Billion MA, Robert-Gero M. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob Agents Chemother 1998; 42: 352-357.
31. 31. Broughton MC, Bard M, Lees ND. Polyene resistance in ergosterol producing strains of Candida albicans. Mycoses 1991; 34: 75-83.
32. 32. Currie B, Sanati H, Ibrahim AS, Edwards JE, Casadevall A, Ghannoum MA. Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Antimicrob Agents Chemother 1995; 39: 1934-1937.
33. 33. Joseph-Horne T, Loeffler RS, Hollomon DW, Kelly SL. Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis. J Med Vet Mycol 1996; 34: 223-225.
34. 34. Joseph-Horne T, Manning N, Holoman D, Kelly S. Nonsterol related resistance in Ustilago maydis to the polyene antifungals, amphotericin B and nystatin. Phytochemistry 1996; 42: 637-639.